朗格汉斯组织细胞增多症111例预后分析  

Prognostic analysis of 111 cases analysis Langerhans cell histiocytosis

作　　者：韩晓丹[1] 周健[1] 喻凤宽[1] 房佰俊[1] 张莉[1] 魏旭东[1] 宋永平[1] 

机构地区：[1]郑州大学附属肿瘤医院河南省肿瘤医院河南省血液病研究所,郑州450008

出　　处：《中国实用内科杂志》2015年第12期1022-1026,共5页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(81370661)

摘　　要：目的探讨朗格汉斯组织细胞增生症患者的预后情况及影响预后的因素。方法回顾性分析1996年9月至2014年5月郑州大学附属肿瘤医院收治的111例朗格汉斯组织细胞增多症患者的临床和随访资料,分析患者的复发情况,对可能影响患者无事件生存时间(EFS)和总生存时间(OS)的因素进行单因素分析。结果多部位骨质受累和多系统受累患者的复发率分别高于非多部位骨质受累和单系统受累的患者(P<0.05)。单因素分析显示,发病年龄≤2岁、多部位骨质受累、多系统受累、有危险器官受累、初始治疗无效的患者无事件生存率和总生存率均显著降低,应用化疗患者的无事件生存率和总生存率均显著升高(P<0.05)。结论发病年龄≤2岁、多部位骨质受累、有危险器官受累及初始治疗后疗效差是影响患者预后的重要因素。Objective To explore the prognosis and the prognostic factors of patients with Langerhans cell histiocytosis. Methods The clinical and follow-up data of 111 cases with Langerhans cell histiocytosis ere collected and retrospectively analyzed. The state of recurrence was analyzed, and factors impacting on event-free survival（EFS） and overall survival（OS） were analyzed by univariate analyses. Results The patients with multisystem involvement and multiple bone involvement had a higher recurrence rate（P〈0.05）. The univariate analyses indicated that the patients with the age of onset less than 2 years old, multiple bone involvement, multisystem involvement, risk organ involvement and a poor response to initial treatment had a lower EFS rate and OS rate, and the patients who had received chemotherapy had a higher EFS rate and OS rate. Conclusion The age of onset less than 2 years old, multiple bone involvement, risk organ involvement and responses to initial treatment are important prognostic factors.

关 键 词：组织细胞增多症 朗格汉斯细胞 复发 无事件生存期 总生存期 

分 类 号：R59[医药卫生—内科学]